Endocyte to Present Data on EC1456 at the European Cancer Congress 2015

WEST LAFAYETTE, Ind., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that data from ongoing phase 1 trials of Endocyte's SMDC EC1456 will be presented at the European Cancer Congress 2015, being held Sept. 25 - 29, 2015, in Vienna, Austria.

The presentation materials will be available on Endocyte's website following presentation at the conference.

Presentation is as follows:

Poster Presentation: An ongoing Phase 1 dose-escalation study of the folic acid-tubulysin
in small-molecule drug conjugate (SMDC) folate-tubulysin EC1456
When: Sunday, Sept. 27, 16:45 – 18:45 p.m. CEST
Poster Session: Early Drug Development
Presenter: Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore

About EC1456

EC1456 is an investigational proprietary, injectable, SMDC consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1456 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. The targeting ligand folate, essential for cell division, has been investigated with vintafolide. EC1456 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT01999738).

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.

CONTACT: Stephanie Ascher, Stern Investor Relations, Inc. (212) 362-1200, stephanie@sternir.com

Source:Endocyte, Inc.